Membrane Protein Antibody Specificity Profiling

Typical antibody quality control (QC) involves evidence of binding to the intended target, while potential antibody cross-reactivity is often overlooked or marginalized. Poor validation of antibodies due to unrecognized cross-reactivity, or even inability to react completely with the intended target, has led to misleading or erroneous conclusions for analyses using them as reagents. Nowadays, it is recognized that rigorous specificity analysis is critical for successful antibody-based drug discovery and development (e.g. CAR-T).

Membrane protein-based antibody specificity profiling

About a quarter of the human proteome encodes membrane proteins, which play critical roles in countless cellular functions and are essential in many disease processes. Over the past 20 years, new technologies and methods have greatly advanced the discovery and development of membrane protein-based drugs, including small molecule drugs and monoclonal antibody (mAb) therapeutics. To efficiently discover therapeutically relevant antibodies, there is a growing shift towards functional screening strategies that allow the rapid isolation of molecules with desired cellular effects. Membrane protein microarray, inspired by the previously developed DNA microarray technology, assembles a large number of membrane proteins to meet the needs of different applications, such as small molecule drug discovery, vaccine development, and antibody development (antibody target identification and antibody specificity profiling). This technology can be used to validate the specificity of antibodies to known membrane protein targets. In addition, membrane protein microarrays can provide additional information by identifying binding to other membrane proteins, thus facilitating the final lead selection in the project to avoid off-target binding.

Antibody specificity profiling at Creative Proteomics

To confirm the specificity of antibodies against protein targets, one obvious way is to screen their binding to as many proteins as possible. Creative Proteomics provides membrane protein microarray screening services designed to better and efficiently assist researchers and professionals in antibody specificity profiling. With a high-throughput cell-based platform, we are committed to providing the best solutions for our customers' antibody specificity analysis. Our service can identify the membrane protein targets of antibodies, allowing sensitive detection of both specific and off-target binding. Specifically, we can help our customers with the following items, including but not limited to:

• Antibody reagent validation
• Therapeutic candidate antibody identification
• Diagnostic antibody characterization

Advantages of our membrane protein microarray service

• A team of experts in molecular biology, proteomics, and biochemistry
• A well-established membrane protein microarray platform containing a variety of membrane proteins
• Compatible with almost biotherapeutics
• Fast project turnaround time, from 3 weeks

Creative Proteomics is dedicated to offering membrane protein-related services to support you at every stage of drug discovery and development, from membrane protein production, to hit identification, to drug candidate selection. In addition to membrane protein microarray leading solution for antibody specificity profiling, we also offer high-quality membrane protein production, surface plasmon resonance (SPR)-based membrane protein-molecule interaction analysis, and membrane protein structure determination. How can we help you? How do I start this service? And how long will it take? If you have any of these questions, contact us and someone from our team will get back to you shortly.

* For Research Use Only. Not for use in diagnostic procedures.